<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254758</url>
  </required_header>
  <id_info>
    <org_study_id>ADR-001-01</org_study_id>
    <nct_id>NCT03254758</nct_id>
  </id_info>
  <brief_title>A Study of ADR-001 in Patients With Liver Cirrhosis</brief_title>
  <official_title>A Phase 1/2 Study of ADR-001 in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rohto Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rohto Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human Phase1/2 study of ADR-001, adipose-derived mesenchymal stem cells&#xD;
      (AD-MSCs). The safety and preliminary efficacy are evaluated in Phase 1 in patients with&#xD;
      liver cirrhosis caused by Hepatitis C or Nonalcoholic Steatohepatitis and a recommended Phase&#xD;
      2 dose is determined by the evaluation. The exploratory efficacy and safety are investigated&#xD;
      against the same target population in Phase 2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with decompensated liver cirrhosis (Child-Pugh score; Grade B) caused by Hepatitis C&#xD;
      or Nonalcoholic Steatohepatitis are enrolled to the study. In Phase 1, one of 3 doses of&#xD;
      AD-MSCs is administered by 1 hour single intravenous infusion. Patients are hospitalized for&#xD;
      1 week and a recommended dose for Phase 2 is determined by the evaluation of the safety and&#xD;
      efficacy. In Phase 2, patients with the same disease criteria are enrolled and dosed to&#xD;
      investigate the exploratory efficacy and safety.&#xD;
&#xD;
      The safety and efficacy are evaluated until 24 weeks after dosing both in Phase 1 and Phase&#xD;
      2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of ADR-001 including the incidence of adverse events (Phase 1)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety will be evaluated based on the medical review of adverse event reports and the results of clinical laboratory tests, vital sign, and physical examinations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement rate of Child-Pugh score (Phase 2)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Improvement rate of Child-Pugh score from the baseline will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of liver function evaluated by Child-Pugh score (Phase 1)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change of liver function from the baseline will be evaluated by Child-Pugh score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of Child-Pugh score (Phase 1)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Improvement rate of Child-Pugh score from the baseline will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of Child-Pugh grade (Phase 1)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Improvement rate of Child-Pugh grade from the baseline will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of liver function evaluated by Child-Pugh score (Phase 2)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change of liver function from the baseline will be evaluated by Child-Pugh score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of Child-Pugh grade (Phase 2)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Improvement rate of Child-Pugh grade from the baseline will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of ADR-001 including the incidence of adverse events (Phase 2)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Safety will be evaluated based on the medical review of adverse event reports and the results of clinical laboratory tests, vital sign, and physical examinations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Decompensated Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 Dose escalation : low Mid High Single administalation of ADR-001&#xD;
Phase 2 The recommended dose of ADR-001</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cell</intervention_name>
    <description>Phase1 The dose of AD-MSCs are escalated from low to mid and high step by step. Each administration is one time via intravenous infusion for one hour.&#xD;
Phase2 The recommended dose of ADR-001 is administrated once a week 4 times. The administration route and time is same method with Phase 1.</description>
    <arm_group_label>Mesenchymal stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ≥ 20 years of age&#xD;
&#xD;
          -  Chronic hepatitis C or nonalcoholic steatohepatitis(NASH)&#xD;
&#xD;
          -  Child-Pugh grade B liver cirrhosis&#xD;
&#xD;
          -  ECOG Performance Status ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis patients other than hepatitis C or NASH&#xD;
&#xD;
          -  Malignant neoplasm (except hepatocellular carcinoma patients without recurrence more&#xD;
             than 2 years)&#xD;
&#xD;
          -  History of venous thrombosis or pulmonary embolism&#xD;
&#xD;
          -  Serum creatinine ≥ 2 mg/dL or T-Bil ≥ 5.0 mg/dL&#xD;
&#xD;
          -  Infection with hepatitis B, HIV, ATLV-1 or parvovirus B19&#xD;
&#xD;
          -  Patients experienced transplantation or cell therapy&#xD;
&#xD;
          -  Pregnancy or positive on pregnancy test&#xD;
&#xD;
          -  Complications of significant heart disease, kidney disorder, or respiratory disease&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuji Terai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Niigata University Medical &amp; Dental Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rohto Pharmaceutical Co., Ltd.</last_name>
    <phone>+81-3-6823-6014</phone>
    <email>adr-001@rohto.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Division of Gastroenterology and Hepatology</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Division of Gastroenterology and Hepatology</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

